Showing results (61-70 of 153) with videos related to

Sort By:
Pageof 16
Cancer Cell|January 30, 2026
Emerging landscape of KRAS inhibitors in cancer treatmentJakob M Riedl, Hiroyuki Matsubara, Reid McNeil, et al.
The Oncologist|April 19, 2002
Between parent and child: negotiating cancer treatment in adolescentsRichard T Penson, Paula K Rauch, Steve L McAfee, et al.
JAMA|November 4, 2004
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trialsThomas G Roberts, Bernardo H Goulart, Lee Squitieri, et al.
Nature Communications|June 14, 2020
Quantification of ongoing APOBEC3A activity in tumor cells by monitoring RNA editing at hotspotsPégah Jalili, Danae Bowen, Adam Langenbucher, et al.
Cancer Research|May 19, 2011
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesisRyan B Corcoran, Gianmarco Contino, Vikram Deshpande, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 29, 2019
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS<sup>G12C</sup> InhibitionMeagan B Ryan, Ferran Fece de la Cruz, Sarah Phat, et al.
The Oncologist|May 29, 2020
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone MetastasesJing Xu, Michaela J Higgins, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2008
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersWyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, et al.
Theranostics|July 23, 2016
Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field ApplicationsDivya Pathania, Hyungsoon Im, Aoife Kilcoyne, et al.
Pageof 16